What’s New with MedDRA Version 21.1 and the MSSO

David W. Richardson, M.D.
Medical Officer, MedDRA MSSO
29 & 30 August 2018

MedDRA was developed under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The activities of the MedDRA Maintenance and Support Services Organization (MSSO) are overseen by an ICH MedDRA Management Committee, which is composed of the six ICH parties (EU, EFPIA, MHLW, JPMA, FDA, PhRMA), the Medicines and Healthcare products Regulatory Agency (MHRA) of the UK, Health Canada, and the WHO (as Observer).
Disclaimer and Copyright Notice

• This presentation is protected by copyright and may, with the exception of the MedDRA and ICH logos, be used, reproduced, incorporated into other works, adapted, modified, translated or distributed under a public license provided that ICH's copyright in the presentation is acknowledged at all times. In case of any adaption, modification or translation of the presentation, reasonable steps must be taken to clearly label, demarcate or otherwise identify that changes were made to or based on the original presentation. Any impression that the adaption, modification or translation of the original presentation is endorsed or sponsored by the ICH must be avoided.

• The presentation is provided "as is" without warranty of any kind. In no event shall the ICH or the authors of the original presentation be liable for any claim, damages or other liability arising from the use of the presentation.

• The above-mentioned permissions do not apply to content supplied by third parties. Therefore, for documents where the copyright vests in a third party, permission for reproduction must be obtained from this copyright holder.

Topics

• What’s New with Version 21.1
  – Summary of Changes (including SMQs)
  – Translation Review
• MedDRA Translations
• Proactive Maintenance
• Update on Points to Consider (PtC) Documents
• MSSO Email Distribution List Opt-In
• Retrieving MedDRA Unzip Passwords Using SSA
• Update on MedDRA IT Tools
• MedDRA Training
• Upcoming Meetings
What's New with MedDRA Version 21.1

- Release on 1 September 2018
- A simple release
- Change request summary:
  - MSSO considered 1,516 change requests, including SMQ requests (not including translation updates)
    - Approved: 1,283
    - Rejected: 229
    - Suspended: 4
- Changes reflect the differences between v21.0 and v21.1
Net Change of Terms per SOC

- Blood and lymphatic system disorders
- Cardiac disorders
- Congenital, familial and genetic disorders
- Ear and labyrinth disorders
- Endocrine disorders
- Eye disorders
- Gastrointestinal disorders
- General disorders and administration site effects
- Hepatobiliary disorders
- Immune system disorders
- Infections and infestations
- Injury, poisoning and procedural complications
- Investigative
- Metabolism and nutrition disorders
- Musculoskeletal and connective tissue disorders
- Neoplasms benign, malignant and unspecified, short term
- Nervous system disorders
- Pregnancy, puerperium and perinatal
- Product issues
- Psychiatric disorders
- Renal and urinary disorders
- Reproductive system and breast disorders
- Respiratory, thoracic and mediastinal disorders
- Skin and subcutaneous tissue disorders
- Social circumstances
- Surgical and medical procedures
- Vascular disorders

Version Report

- List of various types of changes in MedDRA
Summary of SMQ Changes

• No new SMQs added
• 103 level 1 SMQs in production
• 307 changes made in existing SMQs, see the Version Report

Translation Review

• As part of a standard quality process, MSSO has completed a review of MedDRA translation from English into supported languages (except Japanese)
• List of updated terms available in version reports found in download for each supported language
• As usual, users may submit requests for improvements to any translation using WebCR
MedDRA Translations

• Currently MedDRA is available in 11 languages
  – Chinese, Czech, Dutch, English, French, German, Hungarian, Italian, Japanese, Portuguese and Spanish
  – Translation includes all terms and documentation

• Currently working on Korean and Russian
  – Release dates for the new languages are to be determined
Japanese Translation Fee Removed

• Effective 1 January 2019, additional $850 subscription fee for the Japanese translation of MedDRA will be eliminated
• MSSO subscribers will receive all MedDRA languages with their subscription at no additional cost

Proactive Maintenance
Proactivity Request Review

• Proactive maintenance process allows users to address inconsistencies, make corrections or suggest improvements
• 3 proactivity proposals implemented in MedDRA v21.1
  – Differentiation between administration errors/issues and medication errors/product use issues
  – Review of placement of prophylaxis/prevention terms
  – Review of LLTs under PT *Procedural complications*
• Details of implemented changes in What’s New Version 21.1 document

Update on *Points to Consider (PtC) Documents*
PtC Updates v21.1

- Minor changes to examples in Term Selection document
  - Drug diversion
  - Product quality
- Membership lists removed from Term Selection and Data Retrieval and Presentation documents
  - Available on ICH website

PtC Documents – Current and New

<table>
<thead>
<tr>
<th>PtC Category</th>
<th>PtC Document</th>
<th>Purpose</th>
<th>Availability</th>
<th>Languages</th>
<th>Release Cycle</th>
</tr>
</thead>
<tbody>
<tr>
<td>Term Selection</td>
<td>MedDRA Term Selection: Points to Consider</td>
<td>Promote accurate and consistent coding with MedDRA</td>
<td>Now</td>
<td>English and Japanese</td>
<td>Updated with each MedDRA release</td>
</tr>
<tr>
<td></td>
<td>MedDRA Term Selection: Points to Consider Condensed Version</td>
<td>Shorter version focusing on general coding principles to promote accurate and consistent use of MedDRA worldwide</td>
<td>Late 2016</td>
<td>All MedDRA languages (except English and Japanese)</td>
<td>Update as needed</td>
</tr>
<tr>
<td>Data Retrieval and Presentation</td>
<td>MedDRA Data Retrieval and Presentation: Points to Consider</td>
<td>Demonstrate how data retrieval options impact the accuracy and consistency of data output</td>
<td>Now</td>
<td>English and Japanese</td>
<td>Updated with each MedDRA release</td>
</tr>
<tr>
<td></td>
<td>MedDRA Data Retrieval and Presentation: Points to Consider Condensed Version</td>
<td>Shorter version focusing on general retrieval and analysis principles to promote accurate and consistent use of MedDRA worldwide</td>
<td>Late 2018</td>
<td>All MedDRA languages (except English and Japanese)</td>
<td>Update as needed</td>
</tr>
<tr>
<td>General</td>
<td>MedDRA Points to Consider Companion Document</td>
<td>More detailed information, examples, and guidance on specific topics of regulatory importance. Intended as a &quot;living&quot; document with frequent updates based on users’ needs.</td>
<td>Q2 2018</td>
<td>English and Japanese</td>
<td>Updated as needed</td>
</tr>
</tbody>
</table>
PtC Companion Document

Support Documentation

Points to Consider Companion Document and MedDRA Best Practice Documents (click here)

Points to Consider Companion Document

- Points to Consider Companion Document Release 1.0

Best Practice

- Single Case Reporting using Semi-annual Version Control
- Implementation of MedDRA Supplemental Terms
- Primary System Organ Class (SOC) Allocation in MedDRA
- MedDRA Implementation and Versioning for Clinical Trials

MedDRA Email Distribution List
Opt-In
MSSO Email Distribution List Opt-In

- EU General Data Protection Regulation (GDPR)
  - Provisions and requirements to protect personal data
- To be compliant with GDPR, the MSSO will ask MedDRA users to opt-in to its email distribution list
- You will receive an email asking if you wish to remain on the MSSO email distribution list
  - You must provide a positive response to remain on the list
  - If you do not respond, your name will automatically be removed
- You may ask to be added to the list at any time
  - See Contact page on MedDRA website

Retrieving MedDRA Unzip Passwords Using Self-Service Application (SSA)
Retrieving Unzip Passwords Using SSA

Previously, unzip passwords were distributed via broadcast email announcing the MedDRA release.

Beginning with v21.1, unzip passwords no longer distributed in the release announcement email.

Unzip passwords stored in Self-Service Application (SSA)
  - Can be retrieved by MedDRA Point of Contact (POC)

Reasons for change
  - More secure method to distribute password
  - Gives POCs access even if they don’t receive broadcast emails
Retrieve Unzip Passwords via SSA (cont)

- To avoid issues on release day, we strongly encourage POCs to practice retrieving unzip password via the SSA prior to the release.
- Videocast on MedDRA website gives step by step instructions on how to retrieve unzip password: [https://www.meddra.org/training-materials](https://www.meddra.org/training-materials)
  - Under “Tools” section

<table>
<thead>
<tr>
<th>SSA Function in videocast</th>
<th>Start time (min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Retrieve MedDRA ID</td>
<td>2:06</td>
</tr>
<tr>
<td>Retrieve MedDRA Password</td>
<td>4:00</td>
</tr>
<tr>
<td>Retrieve MedDRA Unzip Password</td>
<td>5:27</td>
</tr>
<tr>
<td>Check Organization Status</td>
<td>7:09</td>
</tr>
<tr>
<td>Retrieve Primary Point of Contact (PDC)</td>
<td>10:28</td>
</tr>
<tr>
<td>Generate Certificate for Training Attended</td>
<td>12:10</td>
</tr>
</tbody>
</table>

Questions on Unzip Passwords?

- Email the MSSO Help Desk:

  mssohelp@meddra.org
Update on MedDRA IT Tools

Major Web-Based Browser 3.0 Features

- Ability to view supplemental changes
- Upload terms to extract primary and secondary links
  - Option to export secondary SOC links from the Research Bin and Search results
- Upload terms to run against SMQs
  - Options to use algorithmic and hierarchical SMQs
- Expected by Q4 2018
- MedDRA Desktop Browser update will follow
Purpose of Supplemental view in WBB 3.0:
- Displays changes to MedDRA for the next release immediately after approval
- Improves transparency vs. current supplemental posting
- Not the default view
WBB 3.0 Secondary SOC Information

• Option to extract Secondary SOC* information:
  – Exporting from the research bin
  – Separate feature to upload MedDRA terms and extract hierarchy information

*Primary SOC is the default

WBB 3.0 Secondary SOC Information (cont)

• Example export with Secondary SOC information*

<table>
<thead>
<tr>
<th>Term ID</th>
<th>Term</th>
<th>Code</th>
<th>Level</th>
<th>PT</th>
<th>HLDR</th>
<th>HLST</th>
<th>SOC</th>
<th>Primary SOC</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Allergic cystitis</td>
<td>10031.994</td>
<td>PT</td>
<td>Allergic cystitis</td>
<td>Bladder infections and inflammations</td>
<td>Bladder and bladder neck disorders (excl. calculus)</td>
<td>Genitourinary disorders</td>
<td>Y</td>
</tr>
<tr>
<td>2</td>
<td>Allergic cystitis</td>
<td>10031.994</td>
<td>PT</td>
<td>Allergic cystitis</td>
<td>Allergic conditions</td>
<td>Allergic conditions</td>
<td>Immunologic disorders</td>
<td>N</td>
</tr>
<tr>
<td>3</td>
<td>Anaplastic thyroid cancer</td>
<td>10032.052</td>
<td>PT</td>
<td>Anaplastic thyroid cancer</td>
<td>Thyroid neoplasms, malignant</td>
<td>Exocrine neoplasms, malignant and unspecified (incl. cysts and polyps)</td>
<td>Neoplasms benign, malignant and unspecified (incl. cysts and polyps)</td>
<td>Y</td>
</tr>
<tr>
<td>4</td>
<td>Anaplastic thyroid cancer</td>
<td>10032.052</td>
<td>PT</td>
<td>Anaplastic thyroid cancer</td>
<td>Thyroid neoplasms</td>
<td>Thyroid gland disorders</td>
<td>Endocrine disorders</td>
<td>N</td>
</tr>
<tr>
<td>5</td>
<td>Angiomyolipoma of T-cell lymphoma stage III</td>
<td>10032.049</td>
<td>PT</td>
<td>Angiomyolipoma of T-cell lymphoma stage III</td>
<td>Angiomyolipoma of T-cell lymphoma stage III</td>
<td>Lymphoma non-Hodgkin's T-cell</td>
<td>Neoplasms benign, malignant and unspecified (incl. cysts and polyps)</td>
<td>Y</td>
</tr>
<tr>
<td>6</td>
<td>Angiomyolipoma of T-cell lymphoma stage III</td>
<td>10032.049</td>
<td>PT</td>
<td>Angiomyolipoma of T-cell lymphoma stage III</td>
<td>Angiomyolipoma of T-cell lymphoma stage III</td>
<td>Lymphoma non-Hodgkin's T-cell</td>
<td>Neoplasms benign, malignant and unspecified (incl. cysts and polyps)</td>
<td>Y</td>
</tr>
<tr>
<td>7</td>
<td>Angiomyolipoma of T-cell lymphoma stage III</td>
<td>10032.049</td>
<td>PT</td>
<td>Angiomyolipoma of T-cell lymphoma stage III</td>
<td>Angiomyolipoma of T-cell lymphoma stage III</td>
<td>Lymphoma non-Hodgkin's T-cell</td>
<td>Neoplasms benign, malignant and unspecified (incl. cysts and polyps)</td>
<td>Y</td>
</tr>
<tr>
<td>8</td>
<td>Angiomyolipoma of T-cell lymphoma stage III</td>
<td>10032.049</td>
<td>PT</td>
<td>Angiomyolipoma of T-cell lymphoma stage III</td>
<td>Angiomyolipoma of T-cell lymphoma stage III</td>
<td>Lymphoma non-Hodgkin's T-cell</td>
<td>Neoplasms benign, malignant and unspecified (incl. cysts and polyps)</td>
<td>Y</td>
</tr>
<tr>
<td>9</td>
<td>Central nervous system neoplasm</td>
<td>10037.350</td>
<td>PT</td>
<td>Central nervous system neoplasm</td>
<td>Central nervous system neoplasms</td>
<td>Central nervous system neoplasms malignant and unspecified (incl. cysts and polyps)</td>
<td>Neoplasms benign, malignant and unspecified (incl. cysts and polyps)</td>
<td>Y</td>
</tr>
</tbody>
</table>

*Primary SOC hierarchy information is included by default
• Purpose – assist MedDRA users in applying SMQs to their coded data
• Input:
Output:

SMQ Analysis (cont)

- Planned MVAT 3.0 Updates
  - Ability to run reports on supplemental changes
  - Option to include secondary SOC changes
  - Expected before the end of 2018
Future Plans

• **Mobile MedDRA Browser**
  - Search MedDRA terms and codes via a mobile platform
    - Smart Phone
    - Tablet
  - Similar features as the Web-Based Browser
  - Some features may be limited due to constraints of the mobile platform
  - Expected in 2019

Future Plans (cont)

• **MedDRA Application Program Interface (API)**
  - Software building blocks to provide the best features of MSSO tools (e.g., WBB, MVAT)
  - Allows users to develop their own MedDRA tools
    - Supports users that cannot send data outside their firewalls to use MVAT
    - Provides a proven tool that accurately depicts MedDRA
  - Expected in 2019
Application Program Interfaces - Examples

Data: List of MedDRA Terms
Request: SMQ Analysis

Input → API → Outputs

List of SMQ matches per the inputted term list

Data: List of MedDRA Terms
Request: MedDRA hierarchy

Input → API → Outputs

MedDRA primary & Secondary SOC hierarchy information

The user does not need to know how to apply the input data against MedDRA

MedDRA Training
MSSO Free Training Program

- Formats
  - Face-to-face sessions, webinars, videocasts, YouTube Channel
- Languages
  - English, French, German, Spanish, Mandarin Chinese
- Locations
  - Worldwide and “virtual”

Face to Face Training Session Titles

- Coding with MedDRA
- Safety Data Analysis and Standardised MedDRA Queries (SMQs)
- Getting Started with MedDRA
Webinar Titles

- MedDRA Overview
- Getting Started with MedDRA
- MedDRA Coding Basics
- Advanced MedDRA Coding
- Data Analysis and Query Building with MedDRA
- Standardised MedDRA Queries (SMQs)
- What’s New with MedDRA and the MSSO

Face to Face Training Tab
Webinar Training Tab

MedDRA Training

<table>
<thead>
<tr>
<th>Date</th>
<th>Event Title</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUG  29/2018</td>
<td>What's New with MedDRA Version 29.1 and the MEDD</td>
<td>Webinar</td>
</tr>
<tr>
<td>SEP  12/2018</td>
<td>Getting Started with MedDRA</td>
<td>Webinar</td>
</tr>
<tr>
<td>OCT  04/2018</td>
<td>MedDRA Coding Basics</td>
<td>Webinar</td>
</tr>
<tr>
<td>NOV  15/2018</td>
<td>Standardised MedDRA Queries (SMQA)</td>
<td>Webinar</td>
</tr>
<tr>
<td>DEC  04/2018</td>
<td>Data Analysis and Query Building with MedDRA</td>
<td>Webinar</td>
</tr>
</tbody>
</table>

Upcoming Meetings
U.S. Industry MedDRA User Group Meeting

• Date: Friday, 28 September 2018
• Time: 8:00 – 3:30 PST
• Where:
  Genentech
  Genentech Campus, Building 24
  305 DNA Way
  South San Francisco, California
• Open to all MedDRA users
• Preliminary agenda and registration form posted to User Group page on MedDRA website
• Registration deadline: 12 September 2018

Other MedDRA User Group Meetings – Dates to be Determined

• European User Group Meeting
• India User Group Meeting
• Chinese User Group Meeting
• More details to be posted to User Group page on MedDRA website when available
Thank You

Questions?

David W. Richardson, M.D.

Email: mssohelp@meddra.org